Floatz logo

CHLOROPTIC-P S.O.P. COMPONENT PREDNISOLONE

Small Cell Lung Cancer

Poniard PharmaceuticalsSmall moleculePhase 3Dormant
B
56/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
52/ 100
Competitive Position
65/ 100

Competitive context

109 Active assets in the Small Cell Lung Cancer cohort.

Asset / SponsorPhaseRating
ETOPOSIDE
Sichuan University
Phase 4BB
CIS-DIAMMINEDICHLOROPLATINUM II
National Cancer Institute (NCI)
Phase 4BB
Hycamtin
AbbVie
Phase 4BB
Irinotecan
Sichuan University
Phase 4BB
Carboplatin
University of Maryland, Baltimore
Phase 4BB

View all 50 →

Same molecule, other indications

CHLOROPTIC-P S.O.P. COMPONENT PREDNISOLONE is also rated in:

infantile spasmsDormant
BBB
Indicative ·
79 / 100
View asset →
non-Hodgkin lymphomaDormant
BBB
Indicative ·
74 / 100
View asset →
castration-resistant prostate carcinomaDormant
BBB
Indicative ·
72 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →